News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alkermes plc (ALKS) Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence



1/31/2012 6:26:22 AM

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced the initiation of a pilot study of VIVITROL® (naltrexone for extended-release injectable suspension) in prisoners with a pre-incarceration history of opioid dependence. This open-label study is designed to evaluate the feasibility of initiating treatment with VIVITROL in prison and continuing VIVITROL treatment upon release into the community.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES